Risk factors for invasive fungal disease in heart transplant recipients
Alexander S. Rabin(Office of Infectious Diseases), Sophia Koo(Dana-Farber Brigham Cancer Center), Driele Peixoto(Office of Infectious Diseases), Deborah S. Yokoe(Brigham and Women's Hospital), Michael M. Givertz(Brigham and Women's Hospital), Lindsey R. Baden(Brigham and Women's Hospital), Francisco M. Marty(Brigham and Women's Hospital), Gregory S. Couper(Tufts Medical Center), Margaret M. Shea(Brigham and Women's Hospital)
Cited by 42
Related Papers
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981